Eric Everson, PHD in Boise, ID - Psychologist

Eric Everson, PHD is a Psychologist - Clinical based in Boise, Idaho. Eric Everson is licensed to practice in Idaho (license number PSY-202920) and his current practice location is 500 W Fort St, B114, Boise, Idaho. He can be reached at his office (for appointments etc.) via phone at (208) 422-1108.

NPI number for Eric Everson is 1104258318 and his current mailing address is 500 W Fort St, B114, Boise, Idaho. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1104258318.

Contact Information

	Eric Everson, PHD
	500 W Fort St, B114, Boise, ID 83702-4501
	(208) 422-1108
	Not Available

Healthcare Provider's Profile

Full Name	Eric Everson
Gender	Male
Speciality	Psychologist - Clinical
Location	500 W Fort St, Boise, Idaho
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1104258318
Provider Enumeration Date: 07/30/2013
Last Update Date: 05/02/2016

Medical Identifiers

Medical identifiers for Eric Everson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1104258318	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YP2500X	Counselor - Professional	LPC - 5380 (Idaho)	Secondary
103TC0700X	Psychologist - Clinical	PSY-202920 (Idaho)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Eric Everson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Eric Everson, PHD 500 W Fort St, B114, Boise, ID 83702-4501 Ph: (208) 422-1108	Eric Everson, PHD 500 W Fort St, B114, Boise, ID 83702-4501 Ph: (208) 422-1108

News Archive

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

High levels of troponin I (TNI) protein in the blood helps identify possible heart damage after cancer treatment

TNI is a protein present exclusively in heart cells. The TNI blood concentration is a well-established marker of heart muscle injury that's widely used to diagnose and treat heart attacks and other acute coronary syndromes.

Fructose may not be to blame for obesity

Is fructose being unfairly blamed for the obesity epidemic? Or do we just eat and drink too many calories? Researchers from St. Michael's Hospital reviewed more than 40 published studies on whether the fructose molecule itself causes weight gain.

Dopamine transporter availability predicts ICDs

Reduced striatal dopamine transporter availability is already present in patients with Parkinson's disease who go on to develop impulse control disorders, a study shows.

Eric Everson, PHD - Counselor in Boise, ID